BS-181

BS-181 is a potent and selective CDK7 inhibitor (IC50=21 nM) than Seliciclib (HY-30237) . BS-181 is also against CDK2, CDK5 and CDK9 with IC50 values of 880, 3000 and 4200 nM, respectively (fails to block CDK1, 4 and 6) . BS-181 inhibits a panel of cancer cells growth (IC50=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 has the potential for the research of cancer therapy[1][2].

Product Specifications

CAS Number

[1092443-52-1]

UNSPSC

12352005

Target

Apoptosis; CDK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BS-181.html

Purity

98.10

Smiles

CC(C1=C(N=C(C=C2NCC3=CC=CC=C3)NCCCCCCN)N2N=C1)C

Molecular Formula

C22H32N6

Molecular Weight

380.53

References & Citations

[1]Ali S et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009 Aug 1;69 (15) :6208-15.|[2]Wang BY, et al. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Drug Des Devel Ther. 2016 Mar 16;10:1181-9.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9

Citation 01

Biochem Biophys Res Commun. 2019 Jun 11;513 (4) :967-973.|Cell Rep. 2017 Dec 5;21 (10) :2796-2812.|Theranostics. 2017 Apr 20;7 (7) :1914-1927.|Int J Biol Macromol. 2024 Dec 27:139117.|Universidade de Lisboa. 2021 Dec 21.